Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Maze Therapeutics, Inc. (Nasdaq: MAZE) SEC filings page brings together the company’s public regulatory disclosures, offering a detailed view of how this clinical-stage biopharmaceutical company reports its activities to U.S. regulators. Maze focuses on small molecule precision medicines for kidney and metabolic diseases, and its filings provide context on both its scientific programs and its capital markets activity.
Maze’s filings include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, and financing transactions. For example, Maze has filed 8-Ks to furnish press releases on second and third quarter financial results, to disclose an oversubscribed private placement of common stock and pre-funded warrants, and to document the appointments of a new chief financial officer and a new chairman of the board.
Investors can also review registration statements, such as the company’s Form S-1, which describes Maze’s business, risk factors, and the resale of shares issued in its 2025 private placement. The S-1 outlines Maze’s focus on human genetics, its Compass platform, and its lead programs MZE829 and MZE782, while also confirming its status as an emerging growth company and smaller reporting company.
Through Stock Titan, these filings are updated in near real time from the SEC’s EDGAR system, and AI-powered summaries help explain the key points of lengthy documents. Users can quickly understand what a particular 8-K, S-1, or other filing means for the company without reading every page. Where applicable, filings related to equity financings, registration rights, and governance changes are highlighted so investors can track dilution, board composition, and executive appointments.
For MAZE, monitoring SEC filings is especially relevant for understanding clinical development disclosures, financing capacity, and risk factors associated with its kidney and metabolic disease programs. This page serves as a central resource for reviewing those official documents alongside concise AI-generated explanations.
Maze Therapeutics, Inc. President, R&D & CMO Harold Bernstein exercised stock options for 30,000 shares of common stock at an exercise price of $10.42 per share and then sold 30,000 shares in open-market transactions on the same date.
The sales were executed in two tranches at weighted-average prices of $50.4454 and $51.0150 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025. Following these transactions, he reported direct ownership of 0 common shares and 267,407 options remaining from the underlying award, which continues to vest monthly through October 2027.
MAZE files a Form 144 to sell 74,853 shares of Common Stock via exercise of stock options on 03/10/2026. The filing lists prior 10b5-1 dispositions by Harold Bernstein, including sales of 45,000 shares on 12/29/2025 and 25,156 shares on 01/07/2026
The notice states the method as cash proceeds from the option exercise; timing and final cash‑flow details follow the exercise on 03/10/2026.
Tahir Misbah reported acquisition or exercise transactions in this Form 4 filing.
Maze Therapeutics, Inc. reported that Chief Financial Officer Tahir Misbah received equity awards consisting of a stock option for 40,000 shares and 20,000 restricted stock units, both granted at a price of $0.00 per share.
The option award vests monthly in 1/48 increments, with the first portion vesting on April 1, 2026, as long as he continues serving the company. The restricted stock units vest in four equal annual installments, starting on March 1, 2027, with each unit representing the right to receive one share of common stock when it settles. These RSUs either vest or are cancelled before vesting.
Courtney Phillips reported acquisition or exercise transactions in this Form 4 filing.
Maze Therapeutics, Inc. reported that its General Counsel and Corporate Secretary, Courtney Phillips, received equity awards consisting of stock options and restricted stock units. The grant covers 32,000 options that vest monthly over four years starting on April 1, 2026, and 16,000 RSUs that vest annually in four equal installments beginning on March 1, 2027, in each case conditioned on continued service.
Maze Therapeutics, Inc. chief business and strategy officer Atul Dandekar reported a mix of equity awards, option exercise, and share sales. He received a grant of 38,000 stock options and 19,000 restricted stock units, each at an exercise or acquisition price of $0.00 per share.
On February 27, 2026, he exercised 7,500 stock options at $10.42 per share to acquire 7,500 shares of common stock, then sold 3,739 shares at a weighted average price of $45.134 and 3,761 shares at $45.7238. The sales were made under a Rule 10b5-1 trading plan adopted on September 29, 2025.
Following these transactions, he directly held 10,503 shares of common stock, 59,143 stock options and 19,000 restricted stock units. The new option award vests in 1/48 increments monthly starting April 1, 2026, while the RSUs vest in four annual tranches beginning March 1, 2027.
Maze Therapeutics, Inc. reported that Chief Executive Officer Jason V. Coloma received new equity awards. He was granted a stock option for 150,000 shares with a zero exercise price shown in the filing, vesting in 1/48 monthly tranches starting on April 1, 2026, as long as he remains in service.
Coloma was also granted 75,000 restricted stock units, each representing the right to receive one share of common stock upon settlement. These RSUs vest in four equal annual installments, with the first 1/4 vesting on March 1, 2027 and the remaining tranches vesting on each anniversary, subject to continued service. The RSUs do not expire; they either vest or are cancelled before vesting.
Maze Therapeutics insider awarded stock options and RSUs. On March 2, 2026, a reporting person who is a 10% owner and serves as President, R&D & CMO received 48,000 stock options with an exercise price of $45.61 per share, expiring on March 1, 2036. These options vest monthly over four years, with the first 1/48 tranche on April 1, 2026, contingent on continued service.
The insider was also granted 24,000 restricted stock units, each representing one share of common stock. This RSU award vests in four equal annual installments, starting on March 1, 2027, also subject to continued service. Unvested RSUs either vest on schedule or are cancelled before vesting.
Maze Therapeutics SVP, Finance Amy Bachrodt reported multiple equity transactions on March 2, 2026. She exercised a stock option for 5,000 shares of common stock at $10.42 per share and received a new stock option grant for 32,000 shares plus 16,000 restricted stock units, all held directly.
On the same date, she sold 1,300 shares of common stock at a weighted average price of $44.4414 and 3,700 shares at a weighted average price of $45.4694, in open‑market transactions under a Rule 10b5‑1 trading plan adopted on September 29, 2025. The footnotes note price ranges for these weighted averages and describe monthly vesting for the options and annual vesting tranches for the RSUs, subject to continued service.
Maze Therapeutics, Inc. received an updated Schedule 13G/A from a group of Frazier Life Sciences investment vehicles reporting significant ownership of its common stock. Frazier Life Sciences Public Fund, L.P. directly holds 4,342,266 shares of common stock, representing 9.0% of the class, based on 48,119,444 shares outstanding as of November 3, 2025.
Additional Frazier funds report smaller positions: Frazier Life Sciences X, L.P. holds 75,982 shares (0.2%) and Frazier Life Sciences XI, L.P. holds 149,026 shares (0.3%). Several affiliated Frazier Life Sciences XII entities report no common shares.
The filing notes that these figures exclude prefunded warrants. FLSPF holds warrants to purchase 1,702,935 shares, FLS X 54,280 shares, FLS XI 144,532 shares, and FLS XII 252,231 shares, each subject to a 9.99% beneficial ownership limitation that prevents any holder from exceeding that ownership threshold upon exercise. The reporting group certifies that the securities are not held for the purpose of changing or influencing control of Maze Therapeutics.
Maze Therapeutics, Inc. received an updated Schedule 13G/A from several affiliated Third Rock Ventures funds reporting their ownership of the company’s common stock. Third Rock Ventures IV, L.P. directly holds 4,473,958 shares of common stock, which represents approximately 9.3% of Maze’s outstanding shares based on 48,119,440 shares outstanding as of November 3, 2025. Third Rock Ventures V, L.P. directly holds 950,800 shares, representing about 2.0% of the outstanding stock on the same basis.
Related general partner entities (Third Rock Ventures GP IV, L.P., TRV GP IV, LLC, Third Rock Ventures GP V, L.P., and TRV GP V, LLC) may be deemed to share voting and dispositive power over these shares, but they report no sole voting or dispositive power. The reporting persons expressly disclaim the existence of a “group” for regulatory purposes.